William Blair Analysts Decrease Earnings Estimates for BMY

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Investment analysts at William Blair dropped their FY2027 EPS estimates for shares of Bristol-Myers Squibb in a report released on Wednesday, February 19th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $6.50 for the year, down from their previous estimate of $7.70. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.74 per share. William Blair also issued estimates for Bristol-Myers Squibb's FY2028 earnings at $5.91 EPS.

A number of other equities research analysts have also recently commented on the company. Truist Financial lifted their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Leerink Partnrs raised Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Tuesday, November 12th. Wolfe Research initiated coverage on Bristol-Myers Squibb in a report on Friday, November 15th. They set a "peer perform" rating for the company. Daiwa America raised Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Wednesday, November 13th. Finally, Bank of America restated a "neutral" rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of "Hold" and a consensus target price of $57.86.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock opened at $55.85 on Monday. The company has a market cap of $113.33 billion, a price-to-earnings ratio of -12.63, a price-to-earnings-growth ratio of 2.07 and a beta of 0.45. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.10. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The firm has a 50 day moving average of $56.99 and a 200-day moving average of $54.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%.

Institutional Investors Weigh In On Bristol-Myers Squibb

Several institutional investors have recently modified their holdings of BMY. AMF Tjanstepension AB boosted its position in shares of Bristol-Myers Squibb by 6.9% during the third quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company's stock valued at $31,618,000 after buying an additional 39,419 shares during the last quarter. Swedbank AB lifted its holdings in Bristol-Myers Squibb by 0.9% in the third quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company's stock valued at $162,440,000 after acquiring an additional 28,427 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Bristol-Myers Squibb by 12.7% in the third quarter. Assenagon Asset Management S.A. now owns 64,191 shares of the biopharmaceutical company's stock valued at $3,321,000 after acquiring an additional 7,245 shares during the period. Mediolanum International Funds Ltd lifted its holdings in Bristol-Myers Squibb by 0.5% in the third quarter. Mediolanum International Funds Ltd now owns 88,527 shares of the biopharmaceutical company's stock valued at $4,499,000 after acquiring an additional 484 shares during the period. Finally, Pettinga Financial Advisors LLC lifted its holdings in Bristol-Myers Squibb by 8.7% in the third quarter. Pettinga Financial Advisors LLC now owns 11,108 shares of the biopharmaceutical company's stock valued at $575,000 after acquiring an additional 886 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,823 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were bought at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now directly owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were paid a $0.62 dividend. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.44%. The ex-dividend date of this dividend was Friday, January 3rd. Bristol-Myers Squibb's dividend payout ratio is currently -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.